TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03067766

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Art Therapy
Description: Participate in a comic art creation workshop

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Art Therapy
Description: Participate in a comic art creation workshop

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interview
Description: Undergo qualitative interviews

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interview
Description: Undergo qualitative interviews

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT00907140

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Positron Emission Tomography
Description: FDG PET/CT imaging is performed at baseline, after 2 and 4 weeks of radiation therapy and approximately 3 months after chemoradiation is completed
Study: NCT03345836

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo for Upadacitinib
Description: Matching placebo tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Upadacitinib
Description: Upadacitinib tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Upadacitinib
Description: Upadacitinib tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Upadacitinib
Description: Upadacitinib tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Upadacitinib
Description: Upadacitinib tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Upadacitinib
Description: Upadacitinib tablets
Study: NCT01511289

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Imatinib
Description: 400mg/Tab, QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Radotinib
Description: 100mg or 200mg/Capsule, 300mg or 400mg BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Radotinib
Description: 100mg or 200mg/Capsule, 300mg or 400mg BID
Study: NCT03502759

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CHICA SUDEP module
Description: CHICA reminds physicians to counsel patients/families about the risk of SUDEP.
Study: NCT02458612

Intervention type: OTHER
Group type: OTHER
Intervention: control group
Description: We will apply traditional physiotherapy including upper limb exercises in three times a week for 12 week.
Study: NCT05275270

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo gel
Description: The placebo gel (B) consisted of the gel alone
Study: NCT02458612

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: intervention group
Description: Participants allocated to the experimental group completed three times a week, 12-week mirror therapy combined with progressive strength training. This protocol consisted of mirror therapy with a mirror box, strength training with Thera-band and exercises for scapular dyskinesis. This intensity of training is approximately equal to training at an intensity of 60% to 80% of one-repetition maximum according to National Strength and Conditioning Association (NSCA) protocols. Intensity of exercise is gradually increased 10% bi-weekly.
Study: NCT02815397

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: given in addition to standard of care treatment
Study: NCT02696785

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ixekizumab
Description: Administered SC

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ixekizumab
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixekizumab
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixekizumab
Description: Administered SC

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SC

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adalimumab
Description: Administered SC
Study: NCT01146808

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adefovir dipivoxil and hepatitis B vaccination
Description: Adefovir 10mg po daily, or adjusted for renal function and option for Hepatitis B vaccination, double dose
Study: NCT05108727

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Diode Laser
Description: DL with a wavelength of 810±5 nm, a 400micron diameter, and a power of 1 watt in continuous mode was applied to the MWF at the test sites.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Modified Widman Flap
Description: Periodontal Surgery Technique
Study: NCT04436510

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo
Description: Drug: Matching Placebo~Administration: Oral~Dose: two tablets twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Verdiperstat
Description: Drug: Verdiperstat~Administration: Oral~Dose: 600mg twice daily
Study: NCT05108727

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Modified Widman Flap
Description: Periodontal Surgery Technique
Study: NCT00813007

Intervention type: BEHAVIORAL
Intervention: Questionnaires
Description: 5 Questionnaires at differing times before and after surgery.
Study: NCT04183192

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mepolizumab
Description: Mepolizumab 3 mg administered SC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mepolizumab
Description: Mepolizumab 6 mg administered SC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mepolizumab
Description: Mepolizumab 12 mg administered SC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mepolizumab
Description: Mepolizumab 24 mg administered SC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Reslizumab
Description: Reslizumab 0.1 mg/kg administered IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Reslizumab
Description: Reslizumab 0.2 mg/kg administered IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Reslizumab
Description: Reslizumab 0.4 mg/kg administered IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Reslizumab
Description: Reslizumab 0.8 mg/kg administered IV

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (administered either IV or SC)
Study: NCT03888703

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fractional ablative CO2 laser
Description: Three treatments with a fractional ablative CO2 laser 8 weeks apart
Study: NCT00691197

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Carboxymethylcellulose sodium and Glycerin
Description: Eye drops used at least 4 times per day, 1-2 drops in each eye while wearing contact lenses.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Carboxymethylcellulose sodium
Description: Eye drops used at least 4 times per day, 1-2 drops in each eye while wearing contact lenses.
Study: NCT01344811

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Telemonitoring
Description: The Telemonitoring group will be provided the Smartphone, body composition analyzer and pedometer. They should visit the site once per every 3 months (12 weeks), and measure their body composition during study period. After measurement of body composition, the subjects should make transmit measured information through Smartphone into a centralized server of Smart Care Center. At Smart care Center, care manager will provide remote body composition and activity monitoring and individual obesity case management
Study: NCT01925170

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Molecular Breast Imaging
Description: Molecular breast imaging is a new nuclear medicine technique for imaging the breast. It uses small field of view semiconductor-based gamma cameras that use Cadmium Zinc Telluride detectors. These have superior spatial and energy resolution to conventional sodium iodide detectors.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Conventional Mammography
Description: Mammography is the process of using low-energy X-rays (usually around 30 kVp) to examine the human breast and is used as a diagnostic and a screening tool.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Technetium (99mTc) sestamibi
Description: Technetium (99mTc) sestamibi is a pharmaceutical agent used in nuclear medicine imaging. The drug is a coordination complex consisting of the radioisotope technetium-99m bound to six methoxyisobutylisonitrile (MIBI) ligands.
Study: NCT04751513

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: auricular acupressure
Description: Pressure on auricular point of Shenmen (TF4), Sympathesis (AH6a), Subcortex (AT4), Endocrine (CO18), finger (SF1), and toe (AH2) of the ear.
Study: NCT03637595

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Acupuncture
Description: 3 sessions of acupuncture will be the reference therapy against which the energy medicine intervention is being compared.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Enery Medicine Intervention
Description: 3 sessions performed by Energy Medicine practitioner, who will perform an assessment followed by the intervention.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham Energy Medicine
Description: a non-energy trained confederate to be determined from the clinical research coordinators and non traditional volunteers enrolled administering assessments and providing therapeutic company.
Study: NCT01603121

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lisofylline
Description: Lisofylline single dose of 9 mg/kg continuous intravenous infusion over a 10 hour period, and lisofylline single dose of 12 mg/kg continuous subcutaneous infusion over a 10 hour period during the alternate period 1 week apart.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lisofylline
Description: Lisofylline single dose of 9 mg/kg continuous intravenous infusion over a 10 hour period, and lisofylline single dose of 12 mg/kg continuous subcutaneous infusion over a 10 hour period during the alternate period 1 week apart.
Study: NCT03574701

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin A
Description: The use of Vitamin A , in the treatment of olfactory loss has been previously studied in both animals and humans. These studies have shown promising results in the treatment of olfactory loss.
Study: NCT01344811

Intervention type: OTHER
Group type: OTHER
Intervention: control group
Description: The control group will receive a weighting scale and pedometer. They should perform the same weight measurement (minimum three times a week) like the intervention group during the study, and measured results should be recorded in a diary of self body weight and the number of steps. In addition, the subjects should visit the site once per every three months (12 weeks).
Study: NCT01823822

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oral protein supplement (Tested product)
Description: Test product: oral protein supplement, sweetened flavoured dairy product, type fresh cheese rich in milk protein (15 g/150 grams). Dosage is 2 pots daily, at least 5 days/week for 4 consecutive weeks.
Study: NCT03862482

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Brånemark® 2, Swede-Vent® 2, Screw-Vent® 1 (Configuration 1)
Description: Brånemark® implant placed at sites 2 (left medial) and 5 (right distal), Swede-Vent® implant placed at sites 1 (left distal) and 4 (right medial), Screw-Vent® implant placed at site 3 (para symphysis)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Brånemark® 1, Swede-Vent® 2, Screw-Vent® 2 (Configuration 2)
Description: Brånemark® implant placed at site 3 (para symphysis), Swede-Vent® implant placed at sites 2 (left medial) and 5 (right distal), Screw-Vent® implant placed at sites 1 (left distal) and 4 (right medial)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Brånemark® 2, Swede-Vent® 1, Screw-Vent® 2 (Configuration 3)
Description: Brånemark® implant placed at sites 1 (left distal) and 4 (right medial), Swede-Vent® implant placed at site 3 (para symphysis), Screw-Vent® implant placed at sites 2 (left medial) and 5 (right distal)
Study: NCT02682017

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Pork meat from pigs feed with a standard feed.
Description: 4 week intervention with 700g (raw weight) of pork meat (3x pork burgers (125g raw weight each) + pork mince (325 g raw weight) per week.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pork meat from pigs fed a feed with a Laminarin/fucoidan mix
Description: 4 week intervention with 700g (raw weight) of pork meat (3x pork burgers (125g raw weight each) + pork mince (325 g raw weight) per week from pigs fed animal feed supplemented (5.37 kg/tonne of feed) with spray-dried laminarin and fucoidan (seaweed).
Study: NCT01823822

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Iso-caloric supplement (Control product)
Description: Control product: sweetened flavoured fresh cheese, with low milk protein content (3 g/150 grams). Dosage is 2 pots daily, at least 5 days/week for 4 consecutive weeks.
Study: NCT03077945

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: heart rate variability biofeedback and cognitive reappraisal

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: control tasks
Study: NCT01678807

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MK-8237 6 DU
Study: NCT02705716

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 0.454% w/w stannous fluoride (1100ppm fluoride)
Description: Dentifrice containing 0.454% w/w stannous fluoride (1100ppm fluoride)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: 0.76% sodium monofluorophosphate (1000ppm fluoride)
Description: Dentifrice containing 0.76% sodium monofluorophosphate (1000ppm fluoride)
Study: NCT01678807

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MK-8237 12 DU

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03304483

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 246-km running
Description: Spartathlon 2017
Study: NCT01636869

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: 20 ml of 0.5% bupivacaine for single-shot femoral nerve block will be done at the beginning then another 20 ml of 0.5% bupivacaine for periarticular block will be performed at the end of operation.~Blood sample will be drawn at 60 min after femoral nerve block and before periarticular block, 15, 30, 45, 60 min after periarticular block.
Study: NCT02465892

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pillars4Life
Description: The Pillars4Life program will guide participants through activities that will help to identify stress and anxiety triggers, plan ways to cope with the stress of life and cancer, manage anxiety, deal with chronic pain, and balance competing priorities in life.
Study: NCT04402892

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 35 ml blood, 5 tubes LITHIUM HEPARINATE at each time (hospitalized Patients )
Description: Patients hospitalized for CoV-2-SARS will be sampled at inclusion (Day 0), at day 21, at 3 months and at 6 months .

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 35 ml blood, 5 tubes LITHIUM HEPARINATE at each time (cured Patients)
Description: Patients who have recovered from CoV-2-SARS will be sampled at inclusion (Day 0), at 3 months and at 6 months .
Study: NCT01211262

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMCgp100
Description: For each arm, the study will be divided into two parts: In part 1, dose escalation, the MTD or RP2D for each dosing regimen will be established. In part 2, dose expansion, a cohort of participants will be treated at the RP2D or MTD.
Study: NCT00989430

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prism Adaptation Treatment
Description: Wearing prism goggles and performing visuomotor tasks during therapy sessions.
Study: NCT04166045

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Treatment Location
Description: The device applies transcutaneous electrical nerve stimulation to the bicep

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Verum Treatment Location
Description: The device applies transcutaneous electrical nerve stimulation to the hand
Study: NCT00187707

Intervention type: DRUG
Group type: OTHER
Intervention: Gabapentin
Description: Subjects will take a single dose of 400 mg of gabapentin
Study: NCT01417780

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AB103
Description: AB103 0.25 mg/kg or 0.5 mg/kg administered as a single IV infusion
Study: NCT00759616

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Oxford Partial Knee
Description: Oxford Partial Knee
Study: NCT01465191

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine
Description: Morphine will be given via spinal injection at doses of 50, 100, 150 micrograms as part of a spinal anesthetic for cesarean section

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine
Description: Morphine will be given via spinal injection at doses of 50, 100, 150 micrograms as part of a spinal anesthetic for cesarean section
Study: NCT03396354

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Integrated robotic surgery
Description: Robotic gastrectomy using Single-Site and Firefly technology will be performed. Specifically, two-port surgery using the Single-Site port and an independent trocar along the right flank (for harmonic scalpel) will be used, along with peritumoral injection of indocyanine green via endoscopy the day before surgery to completely visualize the entire lymphatic channel.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional laparoscopic surgery
Description: conventional laparoscopic gastrectomy will be performed.
Study: NCT02161263

Intervention type: OTHER
Intervention: Patient Quality of Life andVision after LASIK Surgery
Description: Patient questionnaire
Study: NCT03122522

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ipilimumab
Description: ipilimumab 3mg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nivolumab
Description: nivolumab 1mg/kg
Study: NCT00628628

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: As Needed Rasburicase
Description: .15 mg/kg IV Over 30 Minutes On Day 1. Day 2-5, once daily as needed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fixed Dose Rasburicase
Description: .15 mg/kg IV Over 30 Minutes Daily
Study: NCT02839681

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anetumab Ravtansine
Description: Administered intravenously (IV) every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anetumab Ravtansine
Description: Administered intravenously (IV) every 3 weeks

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Blood test
Description: Research blood test for eligibility

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Blood test
Description: Research blood test for eligibility
Study: NCT01656759

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Evicel Fibrin Spray
Description: 10cc syringe dose, once at the end of TKA
Study: NCT03515304

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evolocumab
Description: 420 mg evolocumab administered subcutaneously using an autoinjector/pen in NSTEMI patients within 24 hours, or one day, of admission.
Study: NCT02667691

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: SODB Dimpless
Description: Subjects are supplemented with SODB, daily over 3 Months. Each volunteer was seen for the 4 visits: - visit of pre-inclusion, - visit V1, so-called inclusion visit, - visit V2 at 1,5 months and - visit V3 at 3 months

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects are supplemented with placebo, daily over 3 Months. Each volunteer was seen for the 4 visits: - visit of pre-inclusion, - visit V1, so-called inclusion visit, - visit V2 at 1,5 months and - visit V3 at 3 months

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: caloric restriction
Description: Caloric recommendation reduced by 20%

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: caloric restriction
Description: Caloric recommendation reduced by 20%
Study: NCT01417780

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal saline (0.9% sodium chloride) administered as a single IV infusion
Study: NCT03515304

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered subcutaneously using an autoinjector/pen in NSTEMI patients within 24 hours, or one day, of admission.
Study: NCT00493116

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon-beta-1a
Description: dosage and frequency as per Biogen Idec protocol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methylprednisolone
Description: dosage and frequency as per Biogen Idec protocol
Study: NCT03586843

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-64565111
Description: JNJ-64565111 SC will be administered on Day 1 of Treatment Periods 1, 2 and 3 as per the assigned treatment sequence in Part A and as ascending doses on Days 1, 8, 15, 22, 29 and 36 in Part B.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-64565111
Description: JNJ-64565111 SC will be administered on Day 1 of Treatment Periods 1, 2 and 3 as per the assigned treatment sequence in Part A and as ascending doses on Days 1, 8, 15, 22, 29 and 36 in Part B.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-64565111
Description: JNJ-64565111 SC will be administered on Day 1 of Treatment Periods 1, 2 and 3 as per the assigned treatment sequence in Part A and as ascending doses on Days 1, 8, 15, 22, 29 and 36 in Part B.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-64565111
Description: JNJ-64565111 SC will be administered on Day 1 of Treatment Periods 1, 2 and 3 as per the assigned treatment sequence in Part A and as ascending doses on Days 1, 8, 15, 22, 29 and 36 in Part B.
Study: NCT01198392

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: s-1 plus cisplatin
Description: S-1:80 mg/m2/day po twice daily on Day 1-21,cisplatin: 20mg/m2 iv on Day 1-4, repeat every 5 weeks. Number of Cycles: until progression or unacceptable toxicity develops.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-Fu plus cisplatin
Description: 5-Fu 800 mg/m2/d CI 120h ,Cisplatin 20 mg/m2 as a 2 hour i.v. infusion(on day 1 to day 4 )repeat every 4 weeks.~Number of Cycles: until progression or unacceptable toxicity develops.